Checkpoint Inhibitor-Induced Rejection of a Liver Allograft: A Combination of Acute T Cell-Mediated and Antibody-Mediated Rejection

Liver Transpl. 2019 Dec;25(12):1845-1848. doi: 10.1002/lt.25622. Epub 2019 Sep 25.

Authors

Brian T Lee^{1

2}, Brian H Horwich², Shefali Chopra³, Aaron Ahearn^{4

5}, Hyosun H Han^{1

2

5}

Affiliations

¹ Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA.
² Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
³ Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
⁴ Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA.
⁵ USC Transplant Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.

PMID: 31408574
DOI: 10.1002/lt.25622

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Allografts / drug effects
Allografts / immunology
Antineoplastic Agents, Immunological / adverse effects*
Carcinoma, Squamous Cell / diagnosis
Carcinoma, Squamous Cell / drug therapy
End Stage Liver Disease / surgery*
Graft Rejection / blood
Graft Rejection / chemically induced
Graft Rejection / immunology*
Humans
Isoantibodies / blood
Isoantibodies / drug effects
Isoantibodies / immunology
Liver / drug effects
Liver / immunology
Liver Transplantation / adverse effects
Male
Nivolumab / adverse effects*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Skin Neoplasms / diagnosis
Skin Neoplasms / drug therapy
T-Lymphocytes / drug effects
T-Lymphocytes / immunology

Substances

Antineoplastic Agents, Immunological
Isoantibodies
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab